The state of Connecticut currently has 4 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Recruiting
The purpose of the study is to evaluate the efficacy of lacosamide (LCM) versus an Active Comparator chosen based on standard of care (StOC) in severe and nonsevere seizure burden (defined as total minutes of electroencephalographic neonatal seizures (ENS) per hour) in neonates with seizures that are not adequately controlled with previous anti-epileptic drug (AED) treatment.
Gender:
All
Ages:
28 days and below
Trial Updated:
05/08/2024
Locations: Sp0968 106, Hartford, Connecticut
Conditions: Electroencephalographic Neonatal Seizures, Epilepsy
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
Recruiting
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Epilepsy
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
All
Ages:
Between 2 years and 18 years
Trial Updated:
01/30/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Partial Epilepsy
Human Epilepsy Project 3
Recruiting
By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to mak... Read More
Gender:
All
Ages:
13 years and above
Trial Updated:
01/24/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Idiopathic Generalized Epilepsy